A Clinically Informed Approach to Type 2 Diabetes
Tirzee™ (Tirzepatide) supports healthcare professionals in providing comprehensive metabolic care for adults with type 2 diabetes and obesity.
This foundation highlights the broader approach Tirzee™ offers, guiding healthcare professionals in optimizing metabolic care.
Tirzee™ is a once-weekly injectable therapy containing tirzepatide, a dual incretin receptor agonist indicated for the treatment of type 2 diabetes mellitus and obesity.
Tirzee™ acts through dual incretin receptor activation, providing broader metabolic modulation than single-pathway therapies.
Dual receptor activation (GIP and GLP-1) enhances metabolic signaling
Supports insulin sensitivity and glucose regulation
Synergistic effects across pancreas, brain, gut, & adipose tissue
Clinical evidence demonstrates robust and sustained metabolic outcomes with Tirzee.
weight loss achieved over 72 weeks of Tirzee therapy with intensive lifestyle intervention.
*72 weeks of Tirzee (Tirzepatide) led to a total weight change of −24.3% with intensive lifestyle intervention.[2]
people reached an A1C under 7%*
*Tirzee (Tirzepatide) showed robust improvements in glycaemic control and bodyweight, without increased risk of hypoglycaemia.[3]
Fewer apnea events per hour (AHI) with or without Positive Airway Pressure (PAP) therapy*
*Research shows, Tirzee (Tirzepatide) helped adults with obesity lose weight and improve the severity of sleep apnea, making it easier to breathe and feel rested.[4]
Simple steps, expert support, lasting results
The medicine should:
Scientific Evidence Behind Tirzee™
Explore the clinical trials and peer-reviewed research supporting Tirzee's efficacy, safety, and mechanism of action in adults with type 2 diabetes.
Use this calculator to check your body mass index (BMI), which can help you know your weight category.
Your BMI
Enter your height and weight to see your Body Mass Index (BMI)
Getting started is simple. The patient can consult their Health Care Provider (HCP) or schedule a virtual consultation with a licensed HCPs.
Like all medications, GLP-1 treatments can cause side effects. The most common are mild nausea, digestive changes, and decreased appetite which typically improve after the first few weeks.
Treatment begins with a 2.5 mg dose once weekly for the first 4 weeks. After that, the dose is increased to 5 mg once weekly for at least another 4 weeks.
From there, the Health Care Provider (HCP) may adjust the patient’s dose every 4 weeks based on the patient’s progress and how well the patient tolerates the medication. Further dosing options include 7.5 mg and 10 mg.
Tirzee™ is designed for adults with a BMI of 23+ with a weight-related health condition. The patient is a candidate if they’ve struggled with traditional diet and exercise, have weight-related health concerns, or want medical support for sustainable weight loss. A health care provider (HCP) can determine eligibility during their consultation.
Yes, Tirzee™ may be used for patients with obesity and prediabetes to help with weight loss and improve blood sugar control. It works by helping their body use insulin better and reducing appetite.
The doctor will decide if it’s right for the patient based on their health, weight goals, and blood sugar levels.
Tirzepatide is contraindicated in patients with: